NCT06993922

Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Ain Shams University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study aims to compare dexmedetomidine as an adjuvant to bupivacaine in scalp block versus bupivacaine alone for postoperative pain management in patients undergoing craniotomy.

Detailed description

Scalp block is proposed as a multimodal approach to preventing postoperative pain and hemodynamic responses to previous noxious stimulation during the operation. The use of adjuvants, such as dexmedetomidine, a highly selective alpha-2 adrenergic receptor agonist, has recently been studied for its analgesic effects. Dexmedetomidine acts additionally to local anesthetics, prolonging their duration of action.

Conditions

• Dexmedetomidine
• Adjuvant
• Bupivacaine
• Scalp Block
• Postoperative Pain
• Craniotomy

Interventions

Type	Name	Description
OTHER	Scalp block	Patients will receive a scalp block with bupivacaine alone.
OTHER	Scalp block + Dexmedetomidine	Patients will receive a scalp block with dexmedetomidine as an adjuvant to bupivacaine.

Timeline

• Start date: 2025-05-29
• Primary completion: 2025-11-01
• Completion: 2025-11-01
• First posted: 2025-05-29
• Last updated: 2025-05-30

Locations

1 site across 1 country: Egypt